Abstract:Deficient DNA mismatch repair (MMR) results in a strong mutator phenotype known as microsatellite instability (MSI), which is a hallmark of Lynch syndrome-associated cancers. MSI is characterized by length alterations within simple repeated sequences that are called microsatellites. Lynch syndrome is primarily caused by mutations in the MMR genes, mainly MLH1 and MSH2, and less frequently in MSH6, and rarely PMS2, and large genomic rearrangements account for 5-20 % of all mutations. Germ line hemiallelic methylations of MLH1 or MSH2 are termed as epimutations and have been identified as causative of Lynch syndrome. Moreover, germ line 3' deletions of EPCAM gene is involved in MSH2 methylation. MSI is also observed in about 15 % of sporadic colorectal cancer (CRC), gastric cancer (GC), and endometrial cancer (EC), and at lower frequencies in other cancers, often in association with hypermethylation of the MLH1 gene. Trimethylation of histone H3 on Lys36 (H3K36 me3) is an epigenetic histone mark that was required for DNA MMR in vivo. Thus, mutations in the H3K36 trimethyltransferase SETD2 have been reported as a potential cause of MSI. Genetic, epigenetic, and transcriptomic differences have been identified between cancers with and without MSI. Recent comprehensive molecular characterizations of CRC, EC, and GC by The Cancer Genome Atlas indicate that MSI+ cancers are distinct biological entities. The BRAF V600E mutation is specifically associated with sporadic MSI+ CRCs with methylated MLH1, but is not associated with Lynch syndrome-related CRCs. Accumulating evidence indicates a role of interactions between MSI and microRNA (miRNA) in the pathogenesis of MSI-positive (MSI+) cancer. As another new mechanism underlying MSI, overexpression of miR-155 or miR-21 has been shown to downregulate the expression of the MMR genes. Gene targets of frameshift mutations caused by MSI are involved in various cellular functions, including DNA repair (MSH3 and MSH6), cell signaling (TGFBR2 and ACVR2A), apoptosis (BAX), epigenetic regulation (HDAC2 and ARID1A), and miRNA processing (TARBP2 and XPO5), and a subset of MSI+ CRCs reportedly shows the mutated miRNA machinery phenotype. Moreover, microsatellite repeats in miRNA genes, such as hsa-miR-1273c, may be novel MSI targets for CRC, and mutations in noncoding regulatory regions of MRE11, BAX (BaxΔ2), and HSP110 (HSP110ΔE9) may affect the efficiency of chemotherapy. Thus, analyses of MSI and its related molecular alterations in cancers are increasingly relevant in clinical settings, and MSI is a useful screening marker for identifying patients with Lynch syndrome and a prognostic factor for chemotherapeutic interventions. In this review, we summarize recent advances in the pathogenesis of MSI and focus on genome-wide analyses that indicate the potential use of MSI and related alterations as biomarkers and novel therapeutic targets.

Non-classical phenotypes of mismatch repair deficiency and microsatellite instability in primary and metastatic tumors at different sites in Lynch syndrome

The Prevalence of Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

Molecular Screening and Clinicopathologic Characteristics of Lynch-like Syndrome in a Chinese Colorectal Cancer Cohort

Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome

A Pan-Cancer Analysis of Microsatellite Instability As a Predictor of Lynch Syndrome in Chinese Population.

Lower degree of microsatellite instability in colorectal carcinomas from MSH6-associated Lynch syndrome patients

Microsatellite instability: an update

Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome

Expression of MLH1, MSH2, MSH6 and PMS2 in Colorectal Cancer and Their Role in the Screening of Lynch Syndrome

Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer

Null Mismatch Repair Proteins Expression Reveals the Temporal Molecular Events in Lynch Syndrome-Related Cancers

Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome

Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms

DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors

Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome

Data from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells

The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells

Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations

Analysis of clinical characteristics of mismatch repair status in colorectal cancer: a multicenter retrospective study

Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome